Over six months after Novo Nordisk withdrew from the cell therapy sector, its Parkinson’s disease program appears to have secured a new path forward through a licensing agreement with Cellular Intelligence.
The AI-focused biotech obtained rights to the clinical-stage Parkinson’s therapy and also received an equity investment from Novo Nordisk. Financial terms disclosed in the May 11 announcement did not include any upfront payment from Cellular Intelligence, although Novo remains eligible for milestone payments and future royalties if the treatment eventually reaches the market.
Cellular Intelligence will now direct development of STEM-PD, a therapy that converts donor-derived stem cells into neurons before transplanting them into patients’ brains. The candidate is currently being studied in a first-in-human trial, and the company plans to initiate a phase 2 study before year-end, according to Nuno Mendonça, the biotech’s newly appointed CMO.
The Parkinson’s cell therapy field is becoming increasingly competitive. Aspen Neuroscience, for example, is preparing a phase 3 trial for its own treatment, which uses patients’ own cells instead of donor material, after generating encouraging phase 1/2 results.
Cellular Intelligence believes STEM-PD can differentiate itself in the upcoming midstage study through the use of the company’s AI-powered platform, Mendonça said. He indicated that the existing data suggested the company was in a strong position moving forward.
According to co-founder and CEO Micha Breakstone, the company’s manufacturing edge stems from its ability to make small adjustments to stem cells that can produce substantial improvements in areas such as cell viability. Breakstone explained that cell replacement therapies have historically struggled with issues involving scalability, manufacturing and cost, adding that these were precisely the challenges Cellular Intelligence believed it could address.
Novo Nordisk closed its cell therapy division last October and dismissed nearly all 250 employees working in that area as part of a wider restructuring effort. Since then, the company has been working to find external partners for selected assets. Earlier this year, Aspect Biosystems assumed control of Novo’s diabetes-focused cell therapies, accompanied by a Novo investment in the biotech.
Now, Boston-based Cellular Intelligence has become the latest company to benefit from Novo’s strategic retreat from cell therapy, a move introduced under CEO Mike Doustdar early in his tenure.
In the company’s Monday announcement, Jacob Petersen said Novo considered it essential to place the program with an organization capable of advancing it further and expressed confidence that Cellular Intelligence possessed the necessary expertise. Petersen also noted that combining developmental biology, genomics and AI within a single platform represented a promising opportunity not only for cell therapy but for medicine more broadly.
With STEM-PD now transferred and Novo’s collaboration with Heartseed terminated, all of the company’s cell therapy programs that had reached either clinical or late-preclinical development have now been reassigned or discontinued, according to Martin Havtorn Petersen.
Petersen added that the remaining projects in the unit had been at very early stages and indicated that no further deals involving specific cell therapy assets should be expected.
Parkinson’s Research Gains Momentum Through Novo Partnership
Novo Nordisk has entered a strategic agreement with Cellular Intelligence to advance Parkinson’s cell therapy development. The collaboration aims to accelerate research into innovative treatments designed to address neurodegenerative disorders and improve patient outcomes.
The partnership reflects growing pharmaceutical interest in regenerative medicine and advanced neurological therapies. Industry experts believe the agreement could contribute to significant progress in Parkinson’s treatment research over the coming years.
Parkinson’s Cell Therapy Represents Emerging Innovation
Cell therapy has become one of the most promising areas in modern biotechnology, particularly for neurological conditions such as Parkinson’s disease. Researchers are exploring ways to replace damaged cells, restore neurological function, and slow disease progression through advanced regenerative approaches.
The collaboration involving Parkinson’s research highlights the increasing importance of partnerships between pharmaceutical companies and biotech innovators. By combining scientific expertise and research resources, both organizations aim to accelerate therapeutic development and future commercialization opportunities.
Growing Investment in Parkinson’s Drug Development
The global healthcare industry continues to increase investment in treatments targeting neurological disorders. Parkinson’s disease affects millions of people worldwide, creating strong demand for therapies that can improve long-term quality of life and disease management.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
